Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst: Time To Switch Hats? A Mid Cap Fits Now, Maybe A Large Cap?
08:06am, Tuesday, 08'th Dec 2020
The recent FDA approval of Orladeyo (Berotralstat) has completely de-risked BioCryst's future. Orladeyo has the ability to be a "blockbuster drug" and we are of the opinion that it very much has the a
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
08:40am, Monday, 07'th Dec 2020
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today
BioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
10:00am, Sunday, 06'th Dec 2020
—Data presented at the 62nd American Society of Hematology Annual Meeting—
Why BioCryst, Moderna And More Are Moving Today
12:59pm, Friday, 04'th Dec 2020
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopha
Why BioCryst Stock Is Crushing It Today
12:25pm, Friday, 04'th Dec 2020
Investors are cheering the FDA approval of Orladeyo.
BioCryst Pharma News: Why BCRX Stock Is Soaring Today
12:06pm, Friday, 04'th Dec 2020
BioCryst Pharma (BCRX) news for Friday concerning approval from the FDA for one of its drugs has BCRX stock soaring higher. The post BioCryst Pharma News: Why BCRX Stock Is Soaring Today appeared firs
—Significant and sustained reduction in HAE attacks—
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Tuesday, 01'st Dec 2020
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
Allergy Publishes Results from BioCryst's APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks
07:00am, Monday, 30'th Nov 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the journal Allergy has published data from the APeX-J trial, a randomized
BioCryst to Present at Upcoming Virtual Investment Conferences
07:00am, Friday, 20'th Nov 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual HealthCONx on
—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— —Data presented at 2020 Annual Scientific Meeting of the American College of Al
BioCryst Pharmaceuticals: Key Takeaways From Q3 2020
01:08pm, Tuesday, 10'th Nov 2020
On November 5, BioCryst Pharmaceuticals reported results for the 3rd quarter of 2020. BioCryst has a flood of catalysts before it in the coming weeks: Berotralstat approval in USA, Japan, and Europe,
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2020 Results - Earnings Call Transcript
03:09pm, Thursday, 05'th Nov 2020
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2020 Results - Earnings Call Transcript
BioCryst Approvals Close The Window On Short Sellers
06:29am, Thursday, 05'th Nov 2020
Recent Japan PAFSC Review clearance and UK early access for Berotralstat should portend a positive result for December 3rd US PDUFA. BCRX has an institutional hold of around 90%.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 02'nd Nov 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
